Loading...
•
Sep 30, 2022
Mesa Labs Q2 2023 Earnings Report
Reported a revenue increase of 64% and an operating income decrease of 5%.
Key Takeaways
Mesa Laboratories reported a strong rebound in revenue growth for Q2 2023, reaching 12% organically and 18% on a constant currency basis. Profitability also recovered, with adjusted operating income excluding unusual items reaching 27% of revenues.
Revenues increased by 64% compared to the same quarter in the prior year.
Operating income decreased by 5% compared to the same quarter in the prior year.
Clinical Genomics delivered revenues of $18,435, representing 31% of total revenues.
Sterilization and Disinfection Control revenues reached $16,964, representing 21% organic growth.
Revenue by Segment
Forward Guidance
The company is navigating macroeconomic conditions and supply chain complexities, but remains confident in its long-term growth potential due to its exposure to high-growth verticals and its operating model.
Positive Outlook
- Strong revenues growth in 2Q23, reaching 12% organically and 18% on a constant currency basis.
- Profitability recovered strongly, with adjusted operating income excluding unusual items reaching 27% of revenues.
- Strong execution of process improvement initiatives in commercial engagement, labor supply, and supply chain execution.
- Heavy exposure to high growth verticals in biopharmaceutical development, biopharmaceutical production, medical device manufacturing, and clinical genomics.
- Nimble operating model in The Mesa Way allows the company to remain confident in its long-term growth potential.
Challenges Ahead
- Supply chain constraints continue to weigh on growth.
- Navigating macroeconomic conditions that may impact near term demand.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...